 |
|
 |
Status of EU development on a hexavalent,
meninge B vaccine |
|
Assessment and timeline associated
with initiating U.S. trials |
|
Analysis of pricing disparities among
physician supply houses for assessing new approaches to vaccine distribution |
|
Evaluation of current generation efforts
to develop AIDS vaccines |
|
Advantages and disadvantages associated
with developing a new vaccine dosed outside the current schedule of baby well-checks
and vaccinations |
|
Opportunities for utilizing local physician
supply houses in an innovative manner related to vaccine orders placed through a
manufacturer's web site |
|
Assessment of methods for implementing
and tracking vaccine utilization in correctional facilities |
|
Evaluation of reasons for non-participation
by selected hospitals in a vaccine-andantibiotic bundling deal offered through a
major GPO |
 |
|
|
Benefits and risks associated with
promoting an anti-rheumatoid DMARD product to PCPs |
|
Assessment of provider approaches for
obtaining third-party reimbursement on a rigorous physical therapy and dietary program
to treat osteoarthritis |
|
An assessment of selected methods for
redirecting the current approaches of specified MCOs to limiting the usage of COX-2
inhibitors |
|
Evaluations of an approach to mollifying
concerns among rhematologists relative to TNF inhibitors that increase susceptibility
to infection |
 |
|
|
Opportunities, barriers and pricing
dilemmas associated with developing two retinoid products for acne |
|
Potential of dermatologists augmenting
sales of an oral contraceptive promoted for its ancillary skin benefits |
|
Evaluation of consumer choice patterns
in selecting either self-medication, a PCP or a dermatologist for mild-to-moderate
acne |
 |
|
|
Evaluation of late-stage clinical trials
for anti-arrythmic products |
|
Development strategies among anti-platelet
drugs |
|
(Anti-diabetic products) Assessment
of clinical trials and launch strategies for new, oral anti-diabetics: dual- and
pan-PPARs, incretin mimetics, DPP-IV inhibitors |
|
Costs and benefits associated with
initiating Phase III trials on a thrombolytic |
|
Credibility associated with using a
moribund compound for treating atrial arrhythmias |
|
Obstacles confronting the intravenous
IIb/IIIa antagonists as anti-anginal agents |
|
Opportunities and impediments to increasing
the usage of IV corticosteroids by ER physicians following ischemic stroke |
|
Obstacles to expanding the market for
thrombolytics in ischemic stroke: an assessment of the political dynamics between
neurologists and ER physicians |
|
|
Opportunities, barriers and pricing
dilemmas for a product capable of preventing both DVT and atrial fibrillation |
|
|
An assessment of morale among investigators
to a manufacturer's decision about embargoing trial results on an antihypertensive-CHF
product |
|
|
Attitudes among the major CV competitors
relative to developing fixed-dose combinations of antihypertensives and other, non-diuretic
compounds |
|
|
An assessment of the clinical trials
and launch strategy of a non-benzodiazepine anxiolytic |
|
 |
|
|
Opportunities and impediments associated
with marketing SSRIs for social phobias in children |
|
Opportunities for an anti-seizure product
as an anti-depressant adjunct |
|
Obstacles confronting the use of an
anti-narcolepsy product as an anti-depressant adjunct |
|
An ethnographic evaluation of sexual,
cardiovascular and mood side effects among SSRI users |
|
Assessment of EU and US market opportunities
for a 5-HT2 receptor antagonist to treat generalized anxiety disorder |
|
Opportunities and obstacles facing
the development of antidepressants and antipsychotics that affect multiple neurotransmitters |
|
|
The passing of "selectivity"
as a differentiating advance among thought-leading psychopharmacologists |
|
 |
|
|
Assessments of current and pipeline
products for treating hepatitis C |
|
Analysis of a tendency among GI specialists,
despite their denials, to warehouse hepatitis C patients until the launches of the
pegylated versions |
|
Opportunities among internists for
displacing a leading, broad spectrum, oral antibiotic with a new, intravaginally
administered product |
|
Phase III trials assessment and launch
strategy for an anti-sepsis product |
|
The use of unobtrusive measures to
assess what ID specialists and PCPs really think about minimal GI distress as a competitive
feature in oral quinolones |
|
Promoting an AIDS-wasting product to
PCPs |
|
An assessment among thought-leading
GI specialists of treatment options for hepatitis C |
|
|
An assessment of clinical trials and
market potential for a potent anti-infective for treating vancomycin-resistant sepsis |
|
|
An evaluation of key competitive issues
in the hepatitis C market |
|
 |
|
|
Market opportunities for treating mild
cognitive impairment with an existing CNS product |
|
Willingness of neurologists in three
countries to use an existing CNS product for Parkinson's if it can obtain a neuro-protective
labeling |
|
The market among neurologists for botulinum
toxin as a migraine prophylactic |
|
Assessment of current efforts toward
developing products for treating primary progressive MS |
|
Opportunities for using an anti-seizure
product as a migraine therapy |
|
How palliative is the current generation
of Alzheimer's products: a qualitative assessment among 200 neurologists |
|
Market potential of selected products
in development for mild cognitive impairment |
|
Market opportunities for treating early
stage Alzheimer's with an existing CNS product |
 |
|
|
Cocktail approaches for anti-angiogenesis
compounds favored by oncologists who prefer therapies not under protocol |
|
Development status of viral vectors
as oncology vaccines |
|
Interest levels of oncologists toward
a viral vector product approved with a time-to-progression endpoint instead of overall
mortality |
|
The market for promoting a SERM indicated
to prevent osteoporosis as a product to reduce the chances of breast cancer |
|
Analysis of the unique prelaunch versus
post-launch marketing spend and programs in oncology compared to other therapeutic
categories |
|
An assessment of diverse approaches
to managing the development and registration of signal inhibitors, anti-angiogenics
and apoptosis inducers |
|
 |
|
|
Evaluation of formulary acceptability
and obstacles to MCO reimbursement confronting a breath actuated inhaler system |
|
Evaluation of consumer pull-through
benefits from promoting the IgE receptor blocking mechanism to allergic rhinitis
patients |
|
Awareness and early assessments of
thought leaders regarding the development of selected compounds for bronchial asthma |
|
Assessment of selected approaches for
overcoming impediments to thrombolytic usage in COPD |
|
Market impediments to monoclonal antibody
therapies in moderate to severe asthma |
|
Attitudes among thought leading, academic
allergists regarding the use of low dose, mood altering (anxiolytic, antidepressant)
products as adjuncts to early stage, allergy treatment |
|
An analysis of disputed market assumptions
concerning opportunities for newer COPD products |
|
 |
|
|
Obstacles to greater use of SERMs and
bisphosphonates by internists for osteoporosis prevention and treatment |
|
Potential of dermatologists augmenting
sales of an oral contraceptive promoted for its ancillary skin benefits |
|
ROI associated with promoting a SERM
indicated for osteoporosis as a product to reduce the chances for getting breast
cancer |
|
Approaches to developing preferential
loyalty to a manufacturer's oral contraceptives, HRT and other women's products by
targeting female OB/GYNs |
|
An ethnographic study to assess opportunities
and risks associated with communicating a message to PCPs that cardiovascular disease
among women constitutes a special sub-category |
|
Revenue margins, strategies, success
factors and current R&D directions in the oral contraceptive and hormone replacement
therapy markets |
 |
|
|
Regulatory status of Company X's Alpha1-Proteinase
inhibitor |
|
Development status of competitors in
the fibrin sealant category |
|
Assessment of co-development opportunities
in the Factor VIII and Factor IX categories |
|
Analysis of transgenic development
activities by Company L |
